Optimum’s weekly round-up: From an investment in AI-based solutions for sustainable agriculture to new data from hepatocellular carcinoma therapy!

/in

Congratulations to Verona Pharma following the US FDA’s approval of Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients. Optimum is proud to have worked with the fantastic Verona Pharma team in its journey to getting to this  approval for Ohtuvayre, the first inhaled product with a novel mechanism […]

Read more

Death cap poison: the latest weapon in the fight against cancer

/in

The death cap mushroom is feared throughout much of the world because of the deadly toxin it contains, amanitin. But could the poison reputedly used by Agrippina to murder her husband, the Roman emperor Claudius, be used to destroy cancer, asks Richard Staines. Known to modern science as an inhibitor of RNA polymerase II, alpha-Amanitin […]

Read more

Optimum’s weekly round-up: From a Knighthood for STORM Therapeutics Limited’s founder Sir Tony Kouzarides, to an €80 million Series B financing!

/in

STORM Therapeutics Ltd., the clinical stage company pioneering cellular reprogramming through RNA modifications to treat disease, on Monday announced that Tony Kouzarides, PhD, FMedSci, FRS, its Founder & Director and Professor of Cancer Biology, University of Cambridge, will be honoured with a Knighthood for his global impact on disease treatment. Professor Kouzarides, a world leading […]

Read more

Recognition for friend of Optimum Dr. Ruth McKernan at prestigious award ceremony

/in

There was deserved recognition for Dr Ruth McKernan CBE, founder of the biotech AstronauTx, at one of the most prominent events in the life science calendar. Dr McKernan won the Most Significant Contribution to the Mediscience Sector Award at the European Mediscience Awards on Thursday evening. Optimum Strategic Communications proudly worked with AstronauTx to announce […]

Read more

An eventful four-day week!

/in

After a rainy bank holiday weekend, the four-day week was jam-packed with action for the Optimum team, as our client Calliditas recommended shareholders accept a $1 billion+ takeover offer.  Calliditas receives public offer by Asahi Kasei Corporation  Asahi Kasei Corporation announced on Tuesday a public cash offer to acquire all shares and American Depositary Receipts […]

Read more
© Optimum Strategic Communications.